Ultime notizie per Masimo (NASDAQ:MASI) Azioni

Masimo

Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

Masimo Corp

Masivo Silver Corp

4 analysts have expressed a variety of opinions on Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $172.75, along with a high estimate of $180.00 and a low estimate of $170.00. Observing a 5.55% increase, the current average has risen from the previous average price target of $163.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1730919619_0_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Masimo by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$170.00</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Masimo. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Masimo compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Masimo's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Masimo's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MASI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Masimo analyst ratings.</a>
<h2>Delving into Masimo's Background</h2>
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Key Indicators: Masimo's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Masimo's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 9.01%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.22%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Masimo's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.17%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Masimo's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.55%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Masimo's debt-to-equity ratio stands notably higher than the industry average, reaching 0.63. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MASI

4 Analysts Assess Masimo: What You Need To Know

Raymond James analyst Jayson Bedford upgrades Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) from Market Perform to Outperform and announces $170 price target.

News

Upgrades

Price Target

Raymond James Upgrades Masimo to Outperform, Announces $170 Price Target

Wells Fargo analyst Vik Chopra maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $160 to $171.

Wells Fargo Maintains Overweight on Masimo, Raises Price Target to $171

Piper Sandler analyst Jason Bednar maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $165 to $180.

Piper Sandler Maintains Overweight on Masimo, Raises Price Target to $180

Needham analyst Mike Matson reiterates Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Masimo

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) raises FY2024 Adj EPS guidance from $3.80-4.00 to $3.95-4.10 vs $3.88 analyst estimate. Lowers FY2024 sales outlook from $2.08 billion-2.13 billion to $2.08 billion-2.10 billion vs $2.10 billion estimate.

Guidance

Masimo Raises FY2024 Adj EPS Guidance from $3.80-4.00 to $3.95-4.10 vs $3.88 Est; Lowers FY2024 Sales Guidance from $2.08B-2.13B to $2.08B-2.10B vs $2.10B Est

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) is looking for Q4 Adj EPS of $1.35-1.50 vs $1.41 analyst estimate. sees sales of $581.000 million-611.000 million vs $607.35 million estimate.

Masimo Sees Q4 Adj EPS $1.35-1.50 vs $1.41 Est; Sees Sales $581.000M-611.000M vs $607.35M Est

Masimo Sees Q4 Revenue $581M-$611M; Q4 Adj. EPS $1.35-$1.50

Masimo Lowers FY24 Revenue From $2.085B-$2.135B To $2.075B-$2.105B Vs $2.100B Est; Raises FY24 Adj. EPS From $3.80-$4.00 To $3.95-$4.10 Vs $3.88 Est

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.84 by 16.67 percent. The company reported quarterly sales of $504.600 million which beat the analyst consensus estimate of $502.669 million by 0.38 percent. This is a 5.37 percent increase over sales of $478.900 million the same period last year.

Earnings

Earnings Beats

Masimo Q3 2024 Adj. EPS $0.98 Beats $0.84 Estimate, Sales $504.600M Beat $502.669M Estimate

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 10 years by 8.0% on an annualized basis producing an average annual return of 18.82%. Currently, Masimo has a market capitalization of $7.71 billion. 
Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 10 years ago, it would be worth $5,655.84 today based on a price of $144.22 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730752216_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Masimo 10 Years Ago Would Be Worth Today

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement.
Analysts estimate that Masimo will report an earnings per share (EPS) of $0.84. 
Anticipation surrounds Masimo's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat EPS by $0.10, which was followed by a 11.29% increase in the share price the next day.
Here's a look at Masimo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.76</td>
<td>0.69</td>
<td>0.86</td>
<td>0.59</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.86</td>
<td>0.66</td>
<td>1.25</td>
<td>0.63</td>
</tr>
<tr>
<td>Price Change %</td>
<td>11.0%</td>
<td>-12.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730739667_0.png" alt="eps graph" />
<h3>Market Performance of Masimo's Stock</h3>
Shares of Masimo were trading at $144.22 as of November 01. Over the last 52-week period, shares are up 80.19%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Insights on Masimo</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Masimo.
The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.
<h3>Analyzing Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Glaukos, Penumbra and Inspire Medical Systems, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Glaukos, with an average 1-year price target of $145.33, suggesting a potential 0.77% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for Penumbra, with an average 1-year price target of $232.64, implying a potential 61.31% upside.</li>
<li>The consensus among analysts is an Outperform trajectory for Inspire Medical Systems, with an average 1-year price target of $226.6, indicating a potential 57.12% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Glaukos, Penumbra and Inspire Medical Systems, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Masimo</td>
<td>Buy</td>
<td>9.01%</td>
<td>$254.80M</td>
<td>1.17%</td>
</tr>
<tr>
<td>Glaukos</td>
<td>Buy</td>
<td>19.02%</td>
<td>$73.14M</td>
<td>-9.06%</td>
</tr>
<tr>
<td>Penumbra</td>
<td>Buy</td>
<td>11.11%</td>
<td>$200.31M</td>
<td>2.61%</td>
</tr>
<tr>
<td>Inspire Medical Systems</td>
<td>Outperform</td>
<td>29.65%</td>
<td>$166.04M</td>
<td>1.60%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Masimo ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>All You Need to Know About Masimo</h3>
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Understanding the Numbers: Masimo's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Masimo's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 9.01%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Masimo's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 3.22%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Masimo's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.17%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Masimo's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.55%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 0.63, Masimo faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/MASI/earnings">To track all earnings releases for Masimo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Masimo's Upcoming Earnings

<h3 class="wp-block-heading">Bankruptcy Block</h3>
TGI Fridays just rang the "last call" for a financial lifeline, filing for Chapter 11 bankruptcy in Texas. Known for its appetizers, wings, and cocktails, the restaurant chain plans to keep its 39 company-owned locations open as it attempts to restructure its finances and <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">&#8220;explore strategic alternatives&#8221; for the future</a>. 
The 56 U.S. franchises and 40 international locations that are independently owned remain unaffected.
Executive Chairman Rohit Manocha attributed the chain's financial woes to the pandemic's aftermath and some dicey capital structure choices. Private equity firm TriArtisan Capital Partners owns TGI Fridays.
<h3 class="wp-block-heading">New On The Block</h3>
Inland Real Estate Income Trust Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/INRE#OTC">INRE</a>) hired BMO Capital Markets Corp. to advise a potential sale process. The real estate trust, which currently has a $395-million market cap, closed Friday in the red, with its shares down 1.35%, trading at $10.95.
BT (LSE: BT) tapped Citigroup to find a buyer for its financial services segment, Radianz, according <a href="https://www.ft.com/content/6fe5e337-18dc-4a32-8e6e-e759a977b490">to</a> the Financial Times.
DigitalBridge Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>) is seeking to sell Brazil&#8217;s Scala Data Centers, for a price tag of $2 billion, <a href="https://www.bloomberg.com/news/articles/2024-10-24/digitalbridge-is-said-to-explore-a-sale-of-scala-data-centers">per</a> Bloomberg.
ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) is <a href="https://www.reuters.com/business/energy/conocophillips-explores-sale-permian-shale-assets-worth-over-1-billion-sources-2024-10-30/">auctioning</a> shale assets in the Permian Basin, Reuters reported. The oil giant expects more than $1 billion in proceeds. 
See Also: <a href="https://www.benzinga.com/news/24/11/41698607/kamala-harris-ready-if-trump-decides-to-falsely-declare-victory-we-are-prepared-to-respond">Harris &#8216;Ready&#8217; If Trump Decides To &#8216;Falsely&#8217; Declare Victory: &#8216;We Are Prepared To Respond&#8217;</a>
<h3 class="wp-block-heading">Updates From The Block</h3>
BHP Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) backtracks on <a href="https://www.benzinga.com/news/large-cap/24/11/41684205/bhp-backtracks-its-comments-on-abandoning-anglo-american-deal">comments about having "moved on"</a> from its failed Anglo American Plc. BHP Chairman Ken MacKenzie made the comments Wednesday at the company's shareholder meeting in Australia, Bloomberg first <a href="https://www.bloomberg.com/news/articles/2024-10-30/bhp-retreats-from-comments-about-moving-on-from-anglo-bid?sref=TBDibEcD">reported</a> this development. 
Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) CFO Vicki Villacrez discussed an ongoing sale process during a recent earnings call. The company, after closing the sale of OneNeck IT Solutions in September, agreed to divest other assets. Those deals are expected to close later this year.
Blackstone is considering a $3.5-billion purchase of minority stakes in interstate natural gas pipelines owned by EQT Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>), Reuters reported.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41699259/nvidia-rides-ai-wave-to-replace-intel-on-dow-jones-industrial-average-ending-its-25-year-run">Nvidia Rides AI Wave To Replace Intel On Dow Jones Industrial Average, Ending Its 25-Year Run</a></li>
</ul>

Asset Sales

Restaurants

DBRG

INRE

Deal Dispatch: TGI Fridays Goes Bankrupt, BHP Backtracks Comments And More M&A News

The past week has been a rollercoaster ride for Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). From facing a U.S. probe that threatens its iPhone chips production to setting a new sales record for its iPhone, the tech giant has seen it all. Amidst these developments, Apple also found itself in the middle of a patent dispute and witnessed major streaming services moving away from its App Store. Here&#8217;s a recap of the major stories that unfolded over the week.
U.S. Probe Threatens Apple&#8217;s iPhone Chips Production
The U.S. Commerce Department has initiated an investigation into Taiwan Semiconductor Manufacturing Company Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), suspecting a potential breach of sanctions. The probe focuses on whether TSMC violated sanctions by supplying chips to Huawei Technologies via an intermediary firm. This investigation could potentially disrupt the production of chips for Apple&#8217;s iPhones and Macs.
<a href="https://www.benzinga.com/news/24/10/41415320/us-probe-into-potential-sanctions-breach-by-tsmc-threatens-apples-iphone-chips-production">Read the full article here.</a>
Disney and Hulu Bypass Apple&#8217;s App Store
The Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) has stopped allowing customers to subscribe to Hulu and Disney+ via Apple&#8217;s App Store, thereby avoiding the iPhone maker&#8217;s in-app purchase fees. The entertainment giant is now directing customers to its websites to view all plans and directly sign up for a subscription, bypassing the 15% to 30% fee that Apple imposes for each transaction made via in-app purchases.
<a href="https://www.benzinga.com/general/entertainment/24/10/41443702/disney-and-hulu-stream-away-from-apples-30-toll-bridge-what-it-means-for-the-iphone-maker">Read the full article here.</a>
See Also: <a href="https://www.benzinga.com/top-stories/24/10/41529265/apple-hints-at-major-mac-updates-with-rumored-m4-powered-lineup?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Hints At Major Mac Updates With Rumored M4-Powered Lineup</a>
Apple Intelligence Faces Skepticism
Apple&#8217;s much-anticipated new artificial intelligence system, Apple Intelligence, has been met with skepticism. Bloomberg columnist Mark Gurman expressed doubts about the system, suggesting that it may not meet high expectations and consumers might react disappointed or confused when the new AI feature is unveiled next week.
<a href="https://www.benzinga.com/news/24/10/41420086/apple-intelligences-meh-moment-ahead-analyst-predicts-5-months-of-build-up-could-lead-to-a-thats-it">Read the full article here.</a>
Record iPhone Sales in Q3
Apple has set a new sales record for its iPhone during the third quarter of 2024, coinciding with a broader recovery in the global smartphone market. According to Canalys, Apple&#8217;s iPhone sales were narrowly edged out by Samsung Electronics Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>), with both tech giants capturing an 18% market share.
<a href="https://www.benzinga.com/markets/equities/24/10/41328252/apples-iphone-16-powers-record-sales-in-q3-just-behind-samsung-in-global-market-share-battle">Read the full article here.</a>
Apple Wins Patent Dispute Against Masimo
A Delaware jury has ruled in favor of Apple in a patent infringement case against Masimo Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>), awarding Cupertino a symbolic $250 in damages. The jury found that Masimo infringed on Apple's patents related to health technology in older smartwatch models that are no longer on the market.
<a href="https://www.benzinga.com/news/24/10/41562593/apple-secures-victory-in-masimo-patent-dispute-with-token-damages-of-250">Read the full article here.</a>
Read Next:
<a href="https://www.benzinga.com/news/24/10/41545663/russian-president-reportedly-asked-elon-musk-to-restrict-starlink-services-over-taiwan-as-a-favor-to?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Russian President Reportedly Asked Elon Musk To Restrict Starlink Services Over Taiwan As A Favor To Xi Jinping</a>
Photo courtesy: Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>

AAPL

SSNLF

Apple's Week Of Peaks And Valleys: From Record iPhone Sales To Legal And Regulatory Challenges

A Delaware jury has ruled in favor of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) in a patent infringement case against Masimo Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>), awarding Cupertino a symbolic $250 in damages.
What Happened: The jury determined that Masimo infringed on Apple&#8217;s patents related to health technology in older smartwatch models that are no longer on the market, reported Reuters.
The lawsuit, initiated by Apple in 2022, accused Masimo of infringing on two design patents to enhance its own smartwatch offerings. The jury found that Masimo&#8217;s discontinued Freedom and W1 smartwatches violated Apple&#8217;s patents, but current Masimo products were not found to infringe.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Apple&#8217;s legal team sought an injunction against Masimo&#8217;s current products, but this request was denied by the jury. Apple expressed satisfaction with the ruling, stating it protects their innovations.
Meanwhile, Masimo viewed the verdict as a victory, emphasizing that the infringement ruling applied only to outdated models.
See Also: <a href="https://www.benzinga.com/markets/asia/24/10/41509500/nvidia-ceo-jensen-huang-meets-indian-billionaire-mukesh-ambani-duo-forge-partnership-to-build-ai-inf?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia CEO Jensen Huang Meets Indian Billionaire Mukesh Ambani, Duo Forge Partnership To Build AI Infrastructure</a>
The legal battle between Apple and Masimo has been ongoing, with Masimo previously accusing Apple of poaching its employees and copying its pulse oximetry technology.
Why It Matters: The legal skirmish between Apple and Masimo has been a significant point of contention, impacting both companies&#8217; strategies.
Earlier this year, <a href="https://www.benzinga.com/markets/equities/24/01/36632351/apple-dodges-import-ban-in-apple-watch-patent-battle-with-masimo">Apple managed to avoid an import ban</a> on its latest Apple Watch models by redesigning the product, a move that temporarily safeguarded its sales in the U.S. market. However, this decision is not final and could be challenged by the U.S. International Trade Commission.
In response to the looming ban, Apple released versions of its watches without the blood oxygen feature, ensuring continued sales in the U.S.
<a href="https://www.benzinga.com/news/24/01/36671930/apple-watch-versions-minus-blood-oxygen-feature-to-go-on-sale-in-us-as-cupertino-devises-way-to-side">This strategic adjustment</a> highlights Apple&#8217;s adaptability in the face of legal challenges.
Meanwhile, <a href="https://www.benzinga.com/news/24/01/36690640/masimo-ceo-wholeheartedly-feels-apple-watch-users-are-better-off-without-blood-oxygen-monitoring-fea">Masimo&#8217;s CEO Joe Kiani</a> has publicly criticized the reliability of Apple&#8217;s blood oxygen monitoring feature, underscoring the competitive tensions between the two firms.
Looking ahead, Apple is reportedly exploring new functionalities for its Apple Watch, potentially expanding beyond health tracking. <a href="https://www.benzinga.com/news/24/03/37724310/apple-watch-2-0-new-patents-hint-at-expansion-beyond-health-tracking-after-masimo-fiasco">New patent filings</a> suggest the integration of diverse sensors, indicating Apple&#8217;s intent to innovate and diversify its smartwatch offerings.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41481008/the-guy-who-tracked-elon-musk-taylor-swifts-private-jet-wants-to-know-whos-behind-his-suspended-soci?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">The Guy Who Tracked Elon Musk, Taylor Swift&#8217;s Private Jet Wants To Know &#8216;Who&#8217;s Behind&#8217; His Suspended Social Media Accounts</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Legal

Tech

Apple Secures Victory In Masimo Patent Dispute With Token Damages Of $250

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.3% on Friday.
Shares of Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) fell sharply in today's pre-market trading following reports that a judge has blocked the company's<a href="https://www.benzinga.com/m-a/24/10/41533172/capri-holdings-stock-drops-by-half-after-judge-blocks-tapestry-merger"> pending merger with Tapestry.</a>
Following an eight-day trial in which the U.S. Federal Trade Commission argued that a merger between Capri and Tapestry would remove competition from the U.S. handbag space, a U.S. judge has moved to block the pending merger, according to Reuters.
Capri shares tumbled 47.1% to $22.01 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares dipped 19.2% to $6.16 in today's pre-market trading after the company issued fourth-quarter revenue guidance below estimates and cut its FY24 revenue guidance,</li>
<li>The Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBBK#NASDAQ">TBBK</a>) shares declined 15.4% to $46.51 following downbeat quarterly results.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) dipped 8.1% to $5.55 in pre-market trading as the company announced the pricing of public offering of common stock.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares fell 7.8% to $2.36 in pre-market trading. Tevogen Bio recently announced its Artificial Intelligence effort, Tevogen AI, has joined Microsoft for Startups.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares fell 6.6% to $69.89 in pre-market trading following third-quarter results.</li>
<li>Sibanye Stillwater Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) declined 4.6% to $4.73 in pre-market trading after surging more than 12% on Thursday.</li>
<li>The Boston Beer Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) shares fell 4% to $289.80 in pre-market trading following third-quarter results.</li>
<li>Masimo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) shares fell 4% to $135.23 in pre-market trading. Masimo will report third quarter financial results, after the closing bell on Tuesday, Nov. 5.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41528323/jim-cramer-says-hold-on-to-palantir-let-them-walk-it-up-warns-that-travere-therapeutics-is-losing-a">Jim Cramer Says &#8216;Hold On&#8217; To Palantir, &#8216;Let Them Walk It Up&#8217;; Warns That Travere Therapeutics Is Losing A &#8216;Ton Of Money&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

COUR

CPRI

DXCM

JOBY

SBSW

TBBK

TVGN

Capri, Coursera, DexCom And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Masimo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NYSE">MASI</a>) short percent of float has risen 18.66% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 11.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Masimo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729629919_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Masimo has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Masimo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Masimo's peer group average for short interest as a percentage of float is 3.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Masimo?

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) has outperformed the market over the past 10 years by 8.57% on an annualized basis producing an average annual return of 19.92%. Currently, Masimo has a market capitalization of $7.74 billion. 
Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 10 years ago, it would be worth $6,316.76 today based on a price of $144.66 for MASI at the time of writing.
<h3>Masimo's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729524638_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Masimo 10 Years Ago Would Be Worth This Much Today

BTIG analyst Marie Thibault maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Buy and raises the price target from $166 to $170.

BTIG Maintains Buy on Masimo, Raises Price Target to $170

As of Oct. 10, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Travere Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>)</h3>
<ul>
<li>On Sept. 26, Travere Therapeutics announced a voluntary pause of enrollment in its Phase 3 HARMONY study of Pegtibatinase. The company's stock gained around 27% over the past five days and has a <a href="https://www.benzinga.com/quote/TVTX">52-week high of $17.77</a>.</li>
<li>RSI Value: 86.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TVTX Price Action: Shares of Travere Therapeutics gained 15.7% to close at $17.59 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Masimo Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>)</h3>
<ul>
<li>Michelle Brennan, a current member of Masimo's Board, has taken on the role of interim Chief Executive Officer, after Joe Kiani announced his resignation as CEO. In a regulatory filing, the company disclosed that, on September 19, Kiani filed a claim in California state court relating to his employment agreement, as amended, seeking declaratory relief that he had validly terminated his employment for "Good Reason." Masimo said its Board is evaluating Kiani's notice as well as his lawsuit against the company. The company's stock gained around 25% over the past month and <a href="https://www.benzinga.com/quote/MASI">has a 52-week high</a> of $153.93.</li>
<li>RSI Value: 75.44</li>
<li>MASI Price Action: Shares of Masimo rose 2.5% to close at $143.49 on Wednesday.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41266054/s-p-settles-at-record-high-as-apple-amazon-shares-surge-investor-optimism-improves-ahead-of-inflati">S&amp;P Settles At Record High As Apple, Amazon Shares Surge: Investor Optimism Improves Ahead Of Inflation Data</a></li>
</ul>

TVTX

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs

Wells Fargo raised the firm's price target on Masimo (MASI) to $171 from $160 and keeps an Overweight rating on the shares following quarterly resu...

Masimo price target raised to $171 from $160 at Wells Fargo

Wells Fargo analyst Vik Chopra has assigned their bullish stance on MASI stock, giving a Buy rating yesterday. Vik Chopra has given his Buy rating ...

Buy Rating Recommended for Masimo: Strong EPS Performance and Strategic Growth Prospects

BTIG analyst Marie Thibault raised the firm's price target on Masimo (MASI) to $178 from $170 and keeps a Buy rating on the shares after its Q3 ear...

Masimo price target raised to $178 from $170 at BTIG

Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $180.00. The company'...

Piper Sandler Sticks to Their Buy Rating for Masimo (MASI)

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Masimo (MASI – Research Report), with a price target of $170....

Masimo (MASI) Gets a Buy from Stifel Nicolaus

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Five Below downgraded, Snowflake upgraded: Wall Street's top analyst calls

Assessing MedTech impact from potential China tariffs

Masimo ( ($MASI) ) has provided an update. Masimo Corporation has appointed Michelle Brennan as interim CEO with a six-month employment agreement, ...

Masimo Appoints Michelle Brennan as Interim CEO

Masimo ( ($MASI) ) has issued an announcement. Masimo Corporation announced a strategic shift back to its core healthcare business by ending the em...

Masimo Refocuses on Core Healthcare Operations

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Masimo (MASI – Research Report), with a price target of $190....

Comments

Masimo

Notizie

Ultime notizie per Masimo (NASDAQ:MASI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO